Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
Less-intensive Treatment Regimen Effective against Multiple Myeloma
(Posted: 09/23/2010) - Treating patients who have multiple myeloma with less-intensive dosing of bortezomib (Velcade®) reduced toxic side effects without making the treatment less effective, Spanish researchers reported online August 23, 2010, in The Lancet Oncology.
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations
(Posted: 08/12/2010) - Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel, according to results of a phase III trial conducted in Japan.
HPV Status Can Predict Outcome in Oropharyngeal Cancer
(Posted: 06/19/2009, Updated: 08/09/2010) - Patients with advanced oropharyngeal cancer are more likely to survive if their tumors are HPV positive than if they are HPV negative, according to findings presented at the 2009 ASCO meeting in Orlando.
Single-Dose Partial Breast Irradiation Safe for Some Women with Invasive Breast Cancer
(Posted: 07/08/2010, Updated: 08/04/2010) - A study published online June 5, 2010, in The Lancet shows that for some women with invasive breast cancer a single dose of radiotherapy delivered at the time of surgery may be an alternative to a standard course of external beam radiotherapy.
(Posted: 09/23/2010) - Treating patients who have multiple myeloma with less-intensive dosing of bortezomib (Velcade®) reduced toxic side effects without making the treatment less effective, Spanish researchers reported online August 23, 2010, in The Lancet Oncology.
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
Gefitinib Improves Progression-free Survival for Metastatic Lung Cancers with EGFR Mutations
(Posted: 08/12/2010) - Patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC) who received gefitinib (Iressa) had significantly higher response rates and longer progression-free survival compared with patients who received carboplatin plus paclitaxel, according to results of a phase III trial conducted in Japan.
HPV Status Can Predict Outcome in Oropharyngeal Cancer
(Posted: 06/19/2009, Updated: 08/09/2010) - Patients with advanced oropharyngeal cancer are more likely to survive if their tumors are HPV positive than if they are HPV negative, according to findings presented at the 2009 ASCO meeting in Orlando.
Single-Dose Partial Breast Irradiation Safe for Some Women with Invasive Breast Cancer
(Posted: 07/08/2010, Updated: 08/04/2010) - A study published online June 5, 2010, in The Lancet shows that for some women with invasive breast cancer a single dose of radiotherapy delivered at the time of surgery may be an alternative to a standard course of external beam radiotherapy.
